Foster Kennedy syndrome secondary to a giant prolactinoma with a remarkable response to cabergoline [PDF]
Endocrinology, Diabetes & Metabolism Case Reports, 2022 Pituitary adenomas are intracranial neoplasms, usually demonstrating a benign phenotype. We present the case of 21-year-old male with an 18-month history of reduced visual function (acuity and field) in the left eye.
Usama Kanj +5 more
doaj +5 more sources
Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1 [PDF]
Frontiers in Endocrinology, 2019 Context: Overall, giant prolactinomas are rare tumors (4%), especially those larger than 60 mm (1%). Despite the predominance of macroadenoma documented in multiple endocrine neoplasia type 1 (MEN1)-related prolactinoma, only three giant prolactinoma ...
Manoel Martins +1 more
exaly +4 more sources
Giant Prolactinoma Presenting with Neck Pain and Structural Compromise of the Occipital Condyles [PDF]
Journal of Neurological Surgery Reports, 2015 Prolactinomas are the most common form of endocrinologically active pituitary adenoma; they account for ∼ 45% of pituitary adenomas encountered in clinical practice. Giant adenomas are those > 4 cm in diameter.
Laurence Katznelson +2 more
exaly +4 more sources
A case of giant prolactinoma, initially misdiagnosed as sinonasal neuroendocrine carcinoma [PDF]
Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2015 Giant prolactinomas are defined as pituitary tumors greater than 4 cm, often associated with very high prolactin level (>1000 ng/mL). They are relatively rare tumors and can present differently from typical prolactinomas.
Kashif Munir
exaly +4 more sources
Giant Prolactinoma: Challenges in Management. [PDF]
AACE Endocrinol DiabetesProlactinomas are the most common form of pituitary adenomas, 90% of which are microprolactinomas measuring 4 cm with a serum prolactin level of >1000 ng/mL. We report a case of giant prolactinoma causing optic nerve compression that initially responded well to cabergoline and later developed intratumoral hemorrhage requiring transsphenoidal resection ...
Sharma S, Acharya M, Sherpa C.
europepmc +6 more sources
De Novo Psychiatric Disorders in a Woman With Giant Prolactinoma Treated With Cabergoline [PDF]
Clinical Medicine Insights: Case Reports, 2023 Dopamine agonists are the first-line treatment of prolactinomas. The risk of developing de novo psychiatric symptoms during dopamine agonist therapy is low.
Chayma Belhadj Slimane +4 more
doaj +2 more sources
A clinical case of effective treatment of giant prolactinoma in patient with morbid obesity [PDF]
Ожирение и метаболизм, 2014 Numerous studies showed an association between prolactin levels and body weight, with increased prevalence of obesity in patients with prolactinomas. Recent data indicate potential positive influence of cabergoline treatment to metabolic disorders in ...
doaj +3 more sources
Identification of a novel somatic mutation of POU6F2 by whole‐genome sequencing in prolactinoma
Molecular Genetics & Genomic Medicine, 2019 Background Pituitary adenomas (PAs) are one of the most common intracranial tumors; approximately half of PAs are prolactin (PRL)‐secreting PAs (prolactinomas). The genetic alterations prevalent in prolactinomas are unknown.
Yazhou Miao +6 more
doaj +2 more sources
Cerebrospinal fluid rhinorrhoea in young women after 6.5 years of therapy giant prolactinoma with Cabergolin [PDF]
Эндокринная хирургия, 2018 Cerebrospinal fluid (CSF) leak is a rare complication in of the prolactinomas treatment with dopamine agonists. In most cases CSF leak develops within the first three months of treatment starting.
Ludmila I. Astafyeva +8 more
doaj +5 more sources
Ten-year follow-up of a giant prolactinoma. [PDF]
BMJ Case Rep, 2015 Giant prolactinomas are rare pituitary tumours of which management can be a challenge. A 28-year-old man presented with headaches, visual impairment and behavioural changes. Clinically, the patient was found to have hypogonadism and bitemporal hemianopsia.
Fernandes V +3 more
europepmc +8 more sources